889942-56-7

Basic information

• Product Name: tert-Butyl 3-(morpholine-4-carbonyl)piperidine-1-carboxylate
• Synonyms: tert-butyl 3-(morpholine-4-carbonyl)piperidine-1-carboxylate;3-(4-Morpholinylcarbonyl)-1-piperidinecarboxylic acid 1,1-dimethylethyl ester
• CAS NO: 889942-56-7
• Molecular Formula: C15H26N2O4
• Molecular Weight: 298.38
• Mol File: 889942-56-7.mol
• Article Data: 2

Chemical Properties

• Appearance: /
• Density: 1.145
• Refractive Index: 1.507
• Storage Temp.: 2-8°C
• CAS DataBase Reference: tert-Butyl 3-(morpholine-4-carbonyl)piperidine-1-carboxylate(CAS DataBase Reference)
• NIST Chemistry Reference: tert-Butyl 3-(morpholine-4-carbonyl)piperidine-1-carboxylate(889942-56-7)
• EPA Substance Registry System: tert-Butyl 3-(morpholine-4-carbonyl)piperidine-1-carboxylate(889942-56-7)

Safety Data

• Hazardous Substances Data: 889942-56-7(Hazardous Substances Data)

Usage

General Description

Tert-Butyl 3-(morpholine-4-carbonyl)piperidine-1-carboxylate is a chemical compound used in the pharmaceutical industry. It is a piperidine derivative containing a morpholine-4-carbonyl and tert-butyl ester functional groups. tert-Butyl 3-(morpholine-4-carbonyl)piperidine-1-carboxylate has potential applications in drug design and development, particularly for its potential as a central nervous system depressant or analgesic. Tert-Butyl 3-(morpholine-4-carbonyl)piperidine-1-carboxylate may also have potential therapeutic effects for other medical conditions, and further research into its properties and applications is ongoing.

InChI:InChI=1/C15H26N2O4/c1-15(2,3)21-14(19)17-6-4-5-12(11-17)13(18)16-7-9-20-10-8-16/h12H,4-11H2,1-3H3

Upstream product

• 110-91-8 morpholine 
• 71381-75-4 N-(tert-butyloxycarbonyl)nipecotic acid 

Downstream Products

• 35090-96-1 morpholino(piperidin-3-yl)methanone 

Relevant articles and documents

Selective Allosteric Antagonists for the G Protein-Coupled Receptor GPRC6A Based on the 2-Phenylindole Privileged Structure Scaffold

G protein-coupled receptors (GPCRs) represent a biological target class of fundamental importance in drug therapy. The GPRC6A receptor is a newly deorphanized class C GPCR that we recently reported for the first allosteric antagonists based on the 2-arylindole privileged structure scaffold (e.g., 1-3). Herein, we present the first structure-activity relationship study for the 2-arylindole antagonist 3, comprising the design, synthesis, and pharmacological evaluation of a focused library of 3-substituted 2-arylindoles. In a FRET-based inositol monophosphate (IP1) assay we identified compounds 7, 13e, and 34b as antagonists at the GPRC6A receptor in the low micromolar range and show that 7 and 34b display >9-fold selectivity for the GPRC6A receptor over related GPCRs, making 7 and 34b the most potent and selective antagonists for the GPRC6A receptor reported to date.